Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952299 · ClinicalTrials.gov registry record · Phase 3
Oxybutynin for Post-surgical Bladder Pain and Urgency
A Phase 3 study of Overactive Bladder Syndrome and Neuropathic Bladder, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03952299: Recruiting Phase 3 study of Overactive Bladder Syndrome and Neuropathic Bladder, sponsored by University of California, Davis.
NCT03952299 is a Phase 3 study of Overactive Bladder Syndrome and Neuropathic Bladder that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 100 participants, below the 113-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03952299, a Phase 3 study of Overactive Bladder Syndrome and Neuropathic Bladder, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.
Primary Outcome
Mean and peak urgency scores measured using the Pictorial Scale of Bladder Urgency. Children will choose one of four illustrations depicting bladder urgency. These illustrations have been assigned a number 1 through 4. The score of 1 indicates less urgency and a score of 4 indicating greatest urgency.
Conditions Studied
Interventions
- DRUG Oxybutynin Transdermal Patch
- DRUG Oral Oxybutynin
Study Locations (1)
California
- University of California Davis Medical Center (UCDMC) - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
What NCT03952299 shows while recruiting
NCT03952299 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 113-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Overactive Bladder Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Oxybutynin Transdermal Patch is the first listed.
NCT03952299 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03952299 about?
NCT03952299 is a clinical study titled "Oxybutynin for Post-surgical Bladder Pain and Urgency". Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.
What is the current status of trial NCT03952299?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2021-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03952299 study?
This clinical trial studies the following conditions: Overactive Bladder Syndrome, Neuropathic Bladder.
What interventions are being tested in trial NCT03952299?
The interventions under investigation include: Oxybutynin Transdermal Patch (DRUG), Oral Oxybutynin (DRUG).
Who is sponsoring clinical trial NCT03952299?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03952299 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03952299's enrollment target sits among peer trials
100 5th of 11 higher than 6 of 11 other Overactive Bladder Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
COMPLETED · Phase 3
-
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
COMPLETED · Phase 3
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI